Skip to main content

Manuel Comabella Lopez

Dr. Manuel Comabella earned his medical degree at the University of Barcelona, completed his neurology residency at the Neurology Department of the Hospital Universitari Vall d’Hebron (HUVH), and earned his PhD at the Universitat Autònoma de Barcelona. Since 2004, Dr. Manuel Comabella is the Head of the Clinical Neuroimmunology laboratory at the Fundació Institut de Recerca del HUVH. Since June 2008 he works as a clinical neurologist at the Department of Neurology / Neuroimmunology of the MS Centre of Catalonia (Cemcat), HUVH, Barcelona.

Institutions of which they are part

Main researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca
Responsable Laboratori
Multiple Sclerosis Centre of Catalonia
Manuel Comabella Lopez

Manuel Comabella Lopez

Manuel Comabella Lopez

Institutions of which they are part

Main researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca
Responsable Laboratori
Multiple Sclerosis Centre of Catalonia

Dr. Manuel Comabella earned his medical degree at the University of Barcelona, completed his neurology residency at the Neurology Department of the Hospital Universitari Vall d’Hebron (HUVH), and earned his PhD at the Universitat Autònoma de Barcelona. Since 2004, Dr. Manuel Comabella is the Head of the Clinical Neuroimmunology laboratory at the Fundació Institut de Recerca del HUVH. Since June 2008 he works as a clinical neurologist at the Department of Neurology / Neuroimmunology of the MS Centre of Catalonia (Cemcat), HUVH, Barcelona.

From 1996 to 1998, Dr. Manuel Comabella was a Research Fellow in Neuroimmunology at the Center for Neurologic Diseases, Brigham and Women´s Hospital, in Boston. In 2010 was awarded with the Ayudas Merck Serono in the multiple sclerosis research area. In 2011 was awarded by the Spanish Society of Neurology (SEN) with the Biogen Idec Prize to the best publication on demyelinating disorders. In 2013 was awarded by the SEN with the Novartis Prize to the best oral communication and the best publication on demyelinating disorders. In 2014 received the Neurological Disorders Award, scientific modality, granted by the SEN. In 2016 was awarded with the Ayudas Merck Serono in the multiple sclerosis research area. From 2018 to 2020, Dr. Manuel Comabella was a collaborator of the Biomedicine area at the Division of Coordination, Evaluation and Scientific and Technical Follow-up of the State Research Agency, Ministry of Science, Innovation and Universities.

Dr. Manuel Comabella is member of the Editorial Board of Journal of Neuroimmunology and Multiple Sclerosis Journal, member of the Board of the ESNI (European School of Neuroimmunology), and member of the Strategic Group of the IMSGC (International Multiple Sclerosis Genetics Consortium). He is coauthor of 297 documents indexed in MedLine (Scopus: 12916 total citations, with h-index of 54). Dr. Manuel Comabella's research interest lies in the identification of biomarkers related with different aspects of multiple sclerosis and the development of new therapeutic strategies for the disease.

Projects

Validación de marcadores biológicos asociados con la conversión a esclerosis múltiple en pacientes que presentan síndromes clínicos aislados

IP: Manuel Comabella Lopez
Collaborators: Mar Tintore Subirana
Funding agency: Instituto de Salud Carlos III
Funding: 134915
Reference: PI09/00788
Duration: 01/01/2010 - 30/06/2013

Búsqueda de nuevos tratamientos para la esclerosis múltiple mediante screening masivo de librerías de fármacos basado en perfiles de expresión génica usando mapas de conectividad

IP: Manuel Comabella Lopez
Collaborators: Jordi Rio Izquierdo, Búsqueda de nuevos tratamientos para la esclerosis múltiple mediante screening masivo de librerías de fármacos basado en perfile
Funding agency: Fundación Invest. Médica Mutua Madrileña
Funding: 73250
Reference: FMMA/04/2008
Duration: 04/09/2008 - 04/09/2011

Estudio con células madre para encontrar nuevos tratamientos en la esclerosis múltiple

IP: Manuel Comabella Lopez
Collaborators: -
Funding agency: Fundación Caja Navarra
Funding: 42843.62
Reference: CAN-15271
Duration: 01/01/2009 - 31/12/2010

Unitat de Neuroimmunologia Clínica (UNiC)

IP: Unitat de Neuroimmunologia Clínica (UNiC)
Collaborators: Susana Otero Romero, Carlos Nos Llopis, Unitat de Neuroimmunologia Clínica (UNiC), Jaume Sastre Garriga, Jordi Rio Izquierdo, Ingrid Galán Cartaña, Rosalia Horno Ocaña, Manuel Comabella Lopez, Carmen Tur Gomez, Jordi Barquinero Mañez, Herena Eixarch Ahufinger, Montserrat Moreno Sánchez, Mar Tintore Subirana, M Jesus Arevalo Navines, Carmen Espejo Ruiz, Angela Vidal Jordana, Joaquin Castillo Justribo, Mireia Castillo Juarez, Nicolás Miguel Fissolo, Georgina Arrambide García
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 43680
Reference: 2009 SGR 793
Duration: 01/01/2010 - 30/04/2014

Related news

The Spider-MS tool estimates the probability that a patient will experience various long-term clinical events and will help personalize the follow-up and treatment of each person living with the disease.

The results show that live attenuated vaccines against measles, rubella, mumps and varicella do not increase the risk of relapses in people with multiple sclerosis.

Funding has been obtained for 43 projects under the calls for Health R&D&I Projects, Health Technology Development, and Independent Clinical Research

Related professionals

Vanesa Pleguezuelos Hernandez

Vanesa Pleguezuelos Hernandez

Predoctoral researcher
Transfusional Medicine
Read more
Pau Carabí Gassol

Pau Carabí Gassol

Predoctoral researcher
Psychiatry, Mental Health and Addictions
Read more
Polo Figueres, Laura

Polo Figueres, Laura

Physiology and Pathophysiology of the Digestive Tract
Read more
Picos Pouso, Roberto

Picos Pouso, Roberto

Research assistant
Shock, Organ Dysfunction and Resuscitation
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.